1. Home
  2. News
  3. Lumos Diagnostics Holdings Ltd.
  4. FDA Decision for FebriDx
More Lumos Diagnostics Holdings Ltd. news
Lumos Diagnostics Holdings Ltd.ASX: LDX

FDA Decision for FebriDx

Jul 10, 2022 at 8:03 PM EDT · Issued by Lumos Diagnostics Holdings Ltd.

Filed with ASX · Jul 10, 2022 at 8:03 PM EDT · 3 pages · English

On 6ix: 6ix.com/news/fda-decision-for-febridx

Watch Lumos Diagnostics' latest callLumos Diagnostics Holdings (ASX:LDX) Q3 2026 Earnings Call · Replay · Apr 20↗

Lumos Diagnostics Holdings Ltd. on 6ix

Story so far

  • FebriDx Update - Brazil Market Authorisation & New StudyFeb 28, 2022
  • Over 100 Pharmacies in Liverpool UK Launch FebriDx ServiceJan 12, 2022
  • Lumos Provides ViraDx and FebriDx Regulatory UpdateDec 22, 2021

Earlier from Lumos Diagnostics

  • Voluntary SuspensionJul 7, 2022
  • Security Class Reinstatement of Quotation LDXOJun 30, 2022
  • ViraDx Receives Interim Order Authorisation in CanadaJun 26, 2022
  • Security Class Suspension from Quotation LDXOJun 23, 2022
  • Lumos Diagnostics Appoints Doug Ward as CEOJun 21, 2022

Later from Lumos Diagnostics

  • Reinstatement to Official QuotationJul 11, 2022
  • Lumos To Close Sarasota FacilityAug 1, 2022
  • Lumos Files Appeal To The FDA For FebriDxAug 7, 2022
  • Lumos Withdraws from Local Manufacturing ProposalAug 8, 2022
  • Lumos Pilot Manufacturing to Commence in CarlsbadAug 22, 2022
All Lumos Diagnostics news releases↗

Follow Lumos Diagnostics into a list and get an email when it puts out news.

Follow Lumos Diagnostics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer